Abstract
CD8 T cells play a critical role in the host defense against cancers and infectious diseases. However, the presence of antigen-specific CD8 T cells does not always imply that cancers and/or pathogens are efficiently eliminated in the body. Concerning this point, the recent studies suggest the concept of immune exhaustion of CD8 T cells, characterized by their decreased production of IL-2, TNFα, and IFNγ even after antigen stimulation. Thus, continuous stimulation of CD8 T cells by the persistent antigens results in immune exhaustion, which eventually causes immune tolerance against cancers and chronic infections. The identification of immune effector and/or exhausted CD8 T cells by monitoring multiple parameters including T cell exhaustion markers such as PD-1 and Tim-3 and intracellular cytokines is, therefore, crucial to understand the real-time, ongoing immune status. For this purpose, polychromatic flow cytometry is the most common and reliable tool to monitor T cell functions.
We describe here the method for detection of immune-exhaustion status of CD8 T cells from human peripheral blood mononuclear cells (PBMCs). By stimulation of PBMCs with PMA/ionomycin for 6 h, more than 1–2 % of total CD8 T cells are identified as positive in terms of multifunctionality, thus producing multiple cytokines—IL-2, TNFα, and IFNγ—at single-cell level in case of all healthy donors. By contrast, CD8 T cells from certain populations of cancer patients are significantly less effective; less than 0.5 % of CD8 T cells are positive in producing such multiple cytokines. The cutoff value around 0.5 % of CD8 T cells might distinguish patients who would receive beneficial effect by cancer vaccine from those who would not respond to the vaccine. Thus, the remaining capacity to produce multiple cytokines of CD8 T cells might be a critical parameter determining the outcome of cancer patients who receive various kinds of cancer vaccines. The method to monitor the state of multifunctionality of CD8 T cells, as described here, would become more important to understand the immune statues in cancers and chronic infectious diseases such as AIDS and malaria infections.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kakimi K, Isobe M, Uenaka A et al (2011) A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 129:2836
Sabbatini P, Tsuji T, Ferran L et al (2012) Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18:6497
Odunsi K, Matsuzaki J, Karbach J et al (2012) Efficacy of vaccination with recombinant vaccinia and fowl pox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109(15):5797–5802
Kawada J, Wada H, Isobe M et al (2012) Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 130:584
Jäger E, Karbach J, Gnjatic S et al (2006) Recombinant vaccinia/fowl pox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103(39): 14453–14458
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252
Wherry EJ (2011) T cell exhaustion. Nat Immunol 12:492
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Eikawa, S., Mizukami, S., Udono, H. (2014). Monitoring Multifunctionality of Immune-Exhausted CD8 T Cells in Cancer Patients. In: Shiozawa, S. (eds) Arthritis Research. Methods in Molecular Biology, vol 1142. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0404-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0404-4_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0403-7
Online ISBN: 978-1-4939-0404-4
eBook Packages: Springer Protocols